Public Policy Resources

Share

As a recognized expert in cancer health policy, ACS CAN develops reports, white papers, testimony, fact sheets, regulatory comment letters and public policy on a wide range of issues related to preventing cancer and improving the health care system for persons with cancer and survivors.  We encourage you to use this resource to learn more about our issue priorities and policy work. If you can't find something you need, you may contact us by using our contact form and selecting Policy Resources from the drop-down menu.

Search for Resources

FILTER BY:

Woman seeing her physician

Access to Health Care

ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.

View All Access to Health Care Resources

Photo of ACS CAN Volunteers at Advocacy Event to Support Cancer Research Funding

Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

ACS CAN Supports the Clinical Trial Modernization Act (H.R. 3521)

May 22, 2025

The Clinical Trial Modernization Act (H.R. 3521) increase access to clinical trials by allowing clinical trial sponsors to provide financial support to patients for costs associated with their trial participation, including medical cost-sharing like copays, and non-medical expenses such as travel, parking, food and lodging.

Support NIH and NCI in the Fight Against Cancer

May 9, 2025

To ensure that the research being conducted today yields the cancer treatments of tomorrow, Congress must sustain and expand the support it is currently providing. ACS CAN urges Congress to provide $51.3 billion for NIH and $7.93 billion for NCI for FY2026. 

ACS Comments on Importation of Pharmaceutical Products

May 7, 2025

In response to a Department of Commerce request, ACS CAN submitted comments on the role of pharmaceutical products manufactured outside of the U.S. and the potential impacts that tariffs could have on the availability of generic sterile injectable drugs needed by patients with cancer. 

View All Research, Funding and Drug Development Resources

Photo of Making Strides Against Breast Cancer Event Participant

Prevention and Early Detection

ACS CAN advocates for public policies that can prevent nearly half of all cancer deaths by ensuring access to recommended cancer screenings, protecting the public from skin cancer risk, reducing tobacco use and exposure to secondhand smoke and supporting people in increasing physical activity, eating a healthy diet, and managing their weight.

Solo los datos: Gastos de bolsillo y supervivencia del cáncer de seno

June 6, 2025

Un análisis económico realizado en enero de 2025 por ACS CAN y FTI Consulting examinó el impacto de los costos
compartidos en la atención médica de seguimiento tras una mamografía. El estudio mostró que, tras un resultado

El Congreso debe reautorizar el Programa Nacional de Detección Temprana del Cáncer de Mama y de Cuello Uterino

June 6, 2025

La División de Prevención y Control del Cáncer de los Centros para el Control y la Prevención de Enfermedades (CDC) supervisa el Programa Nacional de Detección Temprana del Cáncer de Mama y de Cuello Uterino (NBCCEDP).

The Value of Cancer Registries to Public Health

June 6, 2025

The American Cancer Society Cancer Action Network (ACS CAN) calls on Congress to support the Centers for Disease Control and Prevention’s (CDC) NationalProgram for Cancer Registries (NPCR). Accessible, high-quality and usable registry data is critical to protect health and save lives.

View All Prevention and Early Detection Resources

Doctor and Patient

Health Equity

ACS CAN supports health equity efforts for all Americans so they may receive access to quality care, no matter their race, ethnicity, sexual orientation, income level or ZIP code. 

Solo los datos: Gastos de bolsillo y supervivencia del cáncer de seno

June 6, 2025

Un análisis económico realizado en enero de 2025 por ACS CAN y FTI Consulting examinó el impacto de los costos
compartidos en la atención médica de seguimiento tras una mamografía. El estudio mostró que, tras un resultado

Solo los datos: Desigualdades en el cáncer de seno

May 29, 2025

El cáncer de seno es el tipo de cáncer que se diagnostica con mayor frecuencia en mujeres en EE.UU. Aunque en lasúltimas décadas se han logrado avances sustanciales en la reducción de la mortalidad por esta enfermedad,persisten desigualdades, especialmente entre las mujeres de raza negra.

ACS, ACS CAN and Partners Joint Comments on Patient Navigation Provisions of CY2025 Medicare Physician Fee Schedule Proposed Rule

September 9, 2024

The American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN) along with partners appreciate the opportunity to comment on the Patient Navigation provisions of CY2025 Medicare Physician Fee Schedule.

View All Health Equity Resources